POTSDAM -- Clarkson University researchers from the Biochemistry and Proteomics Laboratory, led by Prof. Costel Darie, have had a manuscript accepted for publication in the Journal of Biological …
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, or purchase a new subscription.
If you are a digital subscriber with an active, online-only subscription then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
POTSDAM -- Clarkson University researchers from the Biochemistry and Proteomics Laboratory, led by Prof. Costel Darie, have had a manuscript accepted for publication in the Journal of Biological Chemistry.
The study investigated the receptor of a new pituitary hormone (Tumor Differentiation Factor, TDF) with differentiation activity on breast and prostate cancer cells. Based on their study, the TDF activates a possible novel pathway.
The hope is to ultimately unveil how this new hormone works. The researchers believe that TDF has anti-cancer activity and potential as a future treatment.
The study is a combination of unique sets of expertise, from protein chemistry and proteomics, to analytical biochemistry, cell biology and neuroscience -- a new direction for Clarkson.
It was performed in Darie’s lab in the Department of Chemistry & Biomolecular Science with support from Mary Ann Gawinowicz’s Protein Chemistry core facility at Columbia University.
Most of the work was performed by Izabela Sokolowska, a Ph.D. student in Darie’s lab.